Project Grant R44CA298704
Award Date
5/1/25
Completion Date
4/30/26
Dollars Obligated
$401K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Georgia, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), part of the Department of Health and Human Services, supports engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptors (VRs) to enhance their efficacy against pancreatic tumors. The $627,272 award aims to expand the repertoire of VRs and optimize the tumor-infiltration capabilities of CAR T cells to improve outcomes for pancreatic cancer patients. The research is being conducted by The Johns...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a universal "off-the-shelf" chimeric antigen receptor (CAR) macrophage cell therapy for the treatment of pancreatic cancer. The $403,687 award will fund research to demonstrate the anti-tumor effects of the phosphatidylserine (PS)-targeted CAR macrophages as an adjuvant therapy to KRAS inhibitor treatment in human pancreatic cancer xenograft models and mouse...
This $587,108 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to enhance the efficacy of non-activated chimeric antigen receptor (CAR) T cells for cancer treatment. The research will investigate methods to improve the transduction efficiency and functional properties of non-activated T cells by modulating type I interferon (IFN1) signaling pathways. Key objectives include: Evaluating the impact of IFN1 blockade on CAR lentivirus transduction...
This $400,000 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a novel pan-cancer CAR-T product targeting MR1, a non-classical MHC molecule expressed on the surface of a variety of tumor cells. The funding will be used by Kure Ai Inc. to: 1) assess MR1 cell surface expression in primary AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3) evaluate the safety of the MR1 CAR-T...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $578,998 to the University of Nebraska Medical Center (UNMC) to conduct research aimed at developing novel targeted therapeutic strategies against pancreatic ductal adenocarcinoma (PDAC), a highly lethal form of pancreatic cancer. The key objectives are to: 1) determine the mechanisms by which the tumor-specific Tn antigen enhances PDAC growth, metastasis, and survival, and identify...
The National Cancer Institute (NCI) awarded a $269,280 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the Translational Genomics Research Institute (TGen) to study the use of a senescent cell-targeted antibody, SIWA318, to improve the efficacy of standard-of-care chemotherapy or immune checkpoint inhibitors in preclinical models of pancreatic ductal adenocarcinoma (PDAC). The project aims to determine the biological effects of SIWA318 on the PDAC tumor microenvironment and evaluate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Sloan-Kettering Institute for Cancer Research provides $1,313,806 in funding to develop and translate chimeric antigen receptor (CAR) T-cell therapies targeting mesothelin for solid tumor treatment. The key products and services to be delivered include: Conducting clinical trials to evaluate the safety and efficacy of mesothelin-targeted CAR T-cell therapies, including...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports the development of a novel binary T-cell therapy strategy to overcome the immunosuppressive tumor microenvironment and enhance anti-tumor immune responses in pancreatic cancer. The $1,301,342 award to Marker Therapeutics Inc., a small disadvantaged business, will fund research to evaluate the kinetics and parameters of a secreted recombinant fusion protein "decoy"...
This $1,377,000 Project Grant award from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) aims to develop a novel oncolytic virus platform called VMG for the treatment of pancreatic ductal adenocarcinoma (PDAC). The key products and services to be delivered under this 3-year project include: Evaluating the VMG oncolytic virus vector's ability to selectively target and destroy PDAC tumor cells while sparing normal tissues, through expression of enzymes to break...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $107,948 to the University of Miami to conduct research on a novel immunotherapy for pancreatic cancer using microRNA-29a. The goal is to determine how microRNA-29a regulates terminally exhausted CD8 T cells in the pancreatic tumor microenvironment and develop a combination therapy to overcome resistance to immune checkpoint blockade in pancreatic ductal adenocarcinoma....